EGFR inhibitor compounds

1. A compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein Formula (I) has the structure:

R 1 is selected from hydrogen, halogen, hydroxy, cyano, an optionally substituted C 1-4 alkyl, an optionally substituted C 1-4 haloalkyl, an optionally substituted C 1-4 alkoxy and an optionally substituted C 1-4 haloalkoxy;

R 2 is a substituted 6-15 membered heteroaryl or a substituted 6-15 membered heterocyclyl, wherein the heteroaryl and the heterocyclyl independently contains 1-4 heteroatoms selected from N, O and S, and the heteroaryl and the heterocyclyl is substituted with an optionally substituted bicyclo[1.1.1]pentyl;

R 3 is selected from hydrogen, an optionally substituted C 1-4 alkyl, an optionally substituted C 3-8 cycloalkyl, an optionally substituted aryl, an optionally substituted heteroaryl and an optionally substituted heterocyclyl, wherein when substituted, R 3 is substituted by one or more substituents selected from halogen, cyano, an unsubstituted C 1-4 alkyl, an optionally substituted aryl, —C(O)R 5A , —SO 2 R 5B , —NHC(O)R 5C and —(CR 6A R 6B ) n NR 7A R 7B ;

X 1 is O, S or NR 4 ;

R 4 is selected from hydrogen, an optionally substituted C 1-4 alkyl, an optionally substituted C 1-4 haloalkyl and an optionally substituted C 3-8 cycloalkyl;

R 5A , R 5B and R 5C are independently selected from hydrogen, an optionally substituted C 1-4 alkyl, an optionally substituted C 1-4 haloalkyl, an optionally substituted C 3-8 cycloalkyl, an optionally substituted aryl, an optionally substituted heteroaryl and an optionally substituted heterocyclyl;

R 6A and R 6B are independently selected from hydrogen, halogen, an optionally substituted C 1-4 alkyl, an optionally substituted C 1-4 haloalkyl and an optionally substituted C 3-8 cycloalkyl;

R 7A and R 7B are independently selected from hydrogen, an optionally substituted C 1-4 alkyl, an optionally substituted C 1-4 haloalkyl and an optionally substituted C 3-8 cycloalkyl;

A 1 is CR 8 ;

R 8 is selected from hydrogen, halogen, cyano, an optionally substituted C 1-4 alkyl, an optionally substituted C 1-4 haloalkyl and an optionally substituted C 3-8 cycloalkyl;

m is 0 or 1; and

n is 0, 1, 2 or 3.

2. The compound of claim 1 , wherein R 2 is selected from a substituted indolyl, a substituted indazolyl, a substituted 4,5,6,7-tetrahydroindazolyl, a substituted

and a substituted

3. The compound of claim 2 , wherein the optionally substituted bicyclo[1.1.1]pentyl substituted on R 2 is a fluoro-substituted bicyclo[1.1.1]pentyl, a chloro-substituted bicyclo[1.1.1]pentyl or a cyano-substituted bicyclo[1.1.1]pentyl.

4. The compound of claim 2 , wherein the optionally substituted bicyclo[1.1.1]pentyl substituted on R 2 is an unsubstituted bicyclo[1.1.1]pentyl.

5. The compound of claim 1 , wherein m is 0.

6. The compound of claim 1 , wherein m is 1.

7. The compound of claim 1 , wherein X 1 is NR 4 .

8. The compound of claim 7 , wherein R 4 is hydrogen or an optionally substituted C 1-4 alkyl.

9. The compound of claim 1 , wherein R 3 is an optionally substituted C 1-4 alkyl.

10. The compound of claim 9 , wherein R 3 is a substituted C 1-4 alkyl.

11. The compound of claim 1 , wherein R 3 is an optionally substituted heterocyclyl.

12. The compound of claim 11 , wherein the optionally substituted heterocyclyl is an optionally substituted monocyclic heterocyclyl.

13. The compound of claim 10 , wherein R 3 is substituted by —(CR 6A R 6B ) n NR 7A R 7B .

14. The compound of claim 13 , wherein n is 0 or 1.

15. The compound of claim 13 , wherein R 6A and R 6B are each hydrogen.

16. The compound of claim 13 , wherein R 7A and R 7B are each an optionally substituted C 1-4 alkyl.

17. The compound of claim 1 , wherein R 1 is an optionally substituted C 1-4 alkoxy.

18. The compound of claim 1 , wherein R 8 is hydrogen.

19. The compound of claim 1 , wherein the compound is selected from:

or a pharmaceutically acceptable salt of any of the foregoing.

20. A pharmaceutical composition comprising an effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, excipient or combination thereof.

21. A method for inhibiting replication of a malignant growth or a tumor comprising contacting the malignant growth or the tumor with an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the malignant growth or tumor is due to a cancer selected from a lung cancer, a pancreatic cancer, a colon cancer, a breast cancer, a prostate cancer, a head and neck cancer, an ovarian cancer, a brain cancer and a kidney carcinoma.

22. A method for ameliorating or treating a cancer comprising contacting a malignant growth or a tumor that is in a subject having the malignant growth or the tumor with an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the malignant growth or tumor is due to a cancer selected from a lung cancer, a pancreatic cancer, a colon cancer, a prostate cancer, a head and neck cancer, an ovarian cancer, a brain cancer and a kidney carcinoma.

23. A method for inhibiting the activity of EGFR comprising providing an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof, to a subject or sample having a cancer cell selected from a lung cancer cell, a pancreatic cancer cell, a colon cancer cell, a breast cancer cell, a prostate cancer cell, a head and neck cancer cell, an ovarian cancer cell, a brain cancer cell and a kidney carcinoma cell, and wherein the EGFR has one or more selected from a deletion in exon 19, an insertion in exon 20, a mutation at L858R and an acquired EGFR T790M mutation.

24. The compound of claim 1 , wherein R 2 is an optionally substituted

an optionally substituted

or an optionally substituted

R 2A , R 2B and R 2C are each an optionally substituted bicyclo[1.1.1]pentyl.